Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in Refractory Primary ITP
NCT05020288Phase 2Unknown
- Sponsor
- Shandong University
- Start
- Sep 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of orelabrutinib in immune thrombocytopenia (ITP), sponsored by Shandong University. Status: unknown.
02
Drugs
orelabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05020288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020288.